Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 4Breast Neoplasms 4Melanoma 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Healthy Participants 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Head and Neck Neoplasms 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Advanced Solid Malignancies 1Advanced Pancreatic Cancer 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Digoxin × Clear all
NCT01162135 2025-05-04

Digoxin for Recurrent Prostate Cancer

Thomas Jefferson University

Phase 2 Completed
16 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Astellas Pharma Inc

Phase 1 Completed
24 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡